Glucotrack, Inc. Amends Warrants; Shareholders Approve Equity Issuances

What Happened
Glucotrack, Inc. filed an 8-K on September 14, 2026 disclosing an amendment to common stock purchase warrants issued in a July/August private placement and reporting the results of a special meeting of stockholders held September 11, 2026. The September 14 amendment prevents exercise or issuance of shares under the Common Warrants until the Company obtains stockholder approval required by Nasdaq Listing Rule 5635(d). At the September 11 special meeting, stockholders approved two proposals authorizing the full issuance of shares related to (1) the ELOC Purchase Agreement with White Lion Capital, LLC and (2) the Bridge financing (conversion of Bridge Notes and exercise of Bridge Warrants).

Key Details

• Amendment to Common Warrants dated September 14, 2026 conditions exercise/issuance on stockholder approval in accordance with Nasdaq Rule 5635(d).
• Special meeting date: September 11, 2026; record date shares outstanding: 10,578,822.
• Votes represented: 3,661,960 shares (≈34.61% of outstanding).
• Proposal 1 (ELOC to White Lion) votes — For: 3,101,374; Against: 228,374; Abstain: 332,212.
• Proposal 2 (Bridge financing conversions/warrants) votes — For: 3,106,894; Against: 226,850; Abstain: 328,216.

Why It Matters
These actions clear the procedural hurdles required by Nasdaq for issuing shares that may exceed 20% of the company’s outstanding common stock (per the July 14, 2026 agreements). For investors, that means the company can now proceed with planned issuances tied to the ELOC and Bridge financings once other conditions are met, and the amended warrant restricts immediate dilution until stockholder approval requirements are satisfied. The approvals and amendment directly affect potential future dilution and the timing of when new shares from the private financings or warrant exercises may be issued.